Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib are very effective for treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Still, they must be taken continuously, and some patients can have trouble tolerating their side effects. Therefore, second-generation BTK inhibitors such as acalabrutinib and zanubrutinib have been designed with the goal of reducing side effects. Therefore, if a patient has a hard time tolerating the side effects of ibrutinib, acalabrutinib or zanubrutinib might be a good treatment option to continue the benefits of BTK inhibition treatment for CLL.
Dr. Jeff Sharman, a hematologist/oncologist at Willamette Valley Cancer Institute in Eugene, OR, discussed the results of a study looking at zanubrutinib and its use in patients who could not tolerate previous BTK inhibitors. These results were presented at the American Society of Hematology (ASH) annual meeting in 2021.
Read the full article on CLL Society's website at: cllsociety.org/2022/07/ash-20...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society
27 июл 2024
